Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
| ▸ | ACP3 | P15309 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2737361 | 0.84 | CYP3A4 (0.43) | P2RX7ACP3GABRA1GABRB2AR | |
| SCHEMBL20314857 | 0.84 | CYP3A4 (0.43) | P2RX7ACP3GABRA1GABRB2AR | |
| SCHEMBL24910232 | 0.83 | TRPA1 (0.52) | P2RX7ARTRPA1HSD11B1CYP3A4 | |
| SCHEMBL2588201 | 0.82 | P2RX7 (0.47) | P2RX7ACP3HSD11B1CNR2ALDH1A1 | |
| SCHEMBL2224459 | 0.82 | P2RX7 (0.47) | P2RX7ACP3HSD11B1CNR2ALDH1A1 | |
| SCHEMBL1258401 | 0.82 | P2RX7 (0.47) | P2RX7ACP3HSD11B1CNR2CYP3A4 | |
| SCHEMBL7330369 | 0.82 | P2RX7 (0.47) | P2RX7ACP3HSD11B1CNR2ALDH1A1 | |
| SCHEMBL13168657 | 0.82 | ACP3 (0.47) | P2RX7ACP3GABRA1GABRB2HSD11B1 | |
| SCHEMBL16105868 | 0.82 | GABRA1 (0.41) | P2RX7ACP3GABRA1GABRB2AR | |
| SCHEMBL23172133 | 0.82 | P2RX7 (0.47) | P2RX7ACP3HSD11B1CNR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 881 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240224783-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240207300-A1 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | SINAI HEALTH SYSTEM (CA) | 2024-06-27 | — | — | US | disclosed |
| WO-2024092116-A1 | COMBINATION OF TEAD INHIBITORS AND EGFR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024059096-A2 | C5AR1 ANTAGONISTS AND USES THEREOF | VANQUA BIO, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024044493-A2 | TREATMENT OF REPEAT EXPANSION DISEASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-02-29 | — | — | WO | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-11858942-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| US-11864458-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-03-01 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173032-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173032-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| EP-0084128-B1 | PROCESS FOR THE PREPARATION OF ALKYLBENZENES SUBSTITUTED BY RADICALS CONTAINING FLUORINE | BAYER AG (DE) | 1987-01-21 | — | — | EP | disclosed |
| EP-0084648-B1 | PROCESS FOR THE ISOMERIZATION OF ALKYLBENZOTRIFLUORIDES | BAYER AG (DE) | 1984-11-07 | — | — | EP | disclosed |
| US-4436941-A | Process for the isomerization of alkylbenzotrifluorides | BAYER AKTIENGESELLSCHAFT (DE) | 1984-03-13 | — | — | US | disclosed |
| EP-0084648-A1 | Process for the isomerization of alkylbenzotrifluorides | BAYER AG (DE) | 1983-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858942-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ADORA2A, ADORA1, ADORA3 | P2RX7 54/4885ACP3 4396/4885GABRA1 175/4885 |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | BRAF, RAF1, ARAF | P2RX7 4869/4885ACP3 2885/4885GABRA1 3660/4885 |
| US-11864458-B2 | Organic electroluminescent materials and devices | RAP1A, L1CAM, SOD1 | P2RX7 2280/4885ACP3 1848/4885GABRA1 2038/4885 |
| US-20240224783-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OCIAD1, ICOSLG | P2RX7 524/4885ACP3 4468/4885GABRA1 1816/4885 |
| US-20240207300-A1 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | WEE2, WEE1, KAT2A | P2RX7 4771/4885ACP3 2630/4885GABRA1 4685/4885 |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | S1PR1, S1PR2, S1PR3 | P2RX7 280/4885ACP3 1998/4885GABRA1 389/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | P2RX7 3221/4885ACP3 3510/4885GABRA1 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.